AVITA Medical Inc
NASDAQ:RCEL
Intrinsic Value
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. [ Read More ]
The intrinsic value of one RCEL stock under the Base Case scenario is 18.47 USD. Compared to the current market price of 8.3 USD, AVITA Medical Inc is Undervalued by 55%.
Valuation Backtest
AVITA Medical Inc
Run backtest to discover the historical profit from buying and selling RCEL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
AVITA Medical Inc
Current Assets | 104m |
Cash & Short-Term Investments | 89.1m |
Receivables | 7.9m |
Other Current Assets | 7m |
Non-Current Assets | 7.6m |
PP&E | 4.3m |
Intangibles | 487k |
Other Non-Current Assets | 2.8m |
Current Liabilities | 13.2m |
Accounts Payable | 3.8m |
Accrued Liabilities | 8.9m |
Other Current Liabilities | 539k |
Non-Current Liabilities | 49.4m |
Long-Term Debt | 39.8m |
Other Non-Current Liabilities | 9.6m |
Earnings Waterfall
AVITA Medical Inc
Revenue
|
50.1m
USD
|
Cost of Revenue
|
-7.6m
USD
|
Gross Profit
|
42.6m
USD
|
Operating Expenses
|
-85m
USD
|
Operating Income
|
-42.4m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
-35.4m
USD
|
Free Cash Flow Analysis
AVITA Medical Inc
RCEL Profitability Score
Profitability Due Diligence
AVITA Medical Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
AVITA Medical Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
RCEL Solvency Score
Solvency Due Diligence
AVITA Medical Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
AVITA Medical Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCEL Price Targets Summary
AVITA Medical Inc
According to Wall Street analysts, the average 1-year price target for RCEL is 27.34 USD with a low forecast of 21.21 USD and a high forecast of 42 USD.
Ownership
RCEL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RCEL Price
AVITA Medical Inc
Average Annual Return | -18.89% |
Standard Deviation of Annual Returns | 56.69% |
Max Drawdown | -92% |
Market Capitalization | 213.2m USD |
Shares Outstanding | 25 710 000 |
Percentage of Shares Shorted | 2.84% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California. The company went IPO on 2012-03-18. The firm is engaged in developing and commercializing a technology platform, which enables point-of-care autologous skin restoration for multiple unmet needs. The company provides treatment solutions derived from the regenerative properties of a patient’s own skin. Its RECELL Autologous Cell Harvesting System (RECELL) enables clinicians to prepare Spray-On Skin Cells, an autologous skin cell suspension, which is sprayed onto the patient to regenerate natural healthy skin. The RECELL System is a single use disposable, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators to achieve the disaggregation and delivery of skin cells. The platform technology of the RECELL System allows for the preparation and delivery of Spray-On Skin Cells, an autologous cellular suspension comprised of the patient’s own skin cells.
Contact
IPO
Employees
Officers
The intrinsic value of one RCEL stock under the Base Case scenario is 18.47 USD.
Compared to the current market price of 8.3 USD, AVITA Medical Inc is Undervalued by 55%.